Up to 50 transplant patients will receive a genetically modified pig kidney in a clinical trial that will launch this summer ...

Corporation (NASDAQ: UTHR) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a pioneering clinical trial of its gene-edited xenotransplantation kidney, named UKidney, ...

United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited pigs could provide a viable option for human patients.

United Therapeutics has already garnered global attention for its trailblazing work in the organ manufacturing arena. But the FDA’s new clearance propels the business closer to potentially ...

eGenesis workers make more than 60 edits to help manage a host of potential issues including rejection, size of the organ and ...

The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a ...

The research offers hope to tens of thousands of patients with kidney failure who are on a long waiting list for an organ ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), a $15.77 billion market cap company with an "Excellent" financial health rating according to InvestingPro, executed a ...

Per filings with the Texas Deparment of Licensing and Regulation, United Therapeutics will construct a 77,448-square-foot facility at 11848 Common Dock Dr. "that will house two types of ...

The small trial will help to establish whether kidneys from genetically modified pigs can be transplanted into people safely and effectively.

size of the organ and even pig retroviruses that could potentially infect humans. Another biotech company, United Therapeutics, announced this week that it had received the green light from the ...